Loading the section
The price of BioMarin Pharmaceutical Inc. (BMRN) on October 9, 2026 is 54.80 USD, -0.16% on the day. Over 52 weeks the stock traded between 49.26 USD and 70.98 USD; the price now sits 26% of the way up that range. Over the past year the price changed by +0.20%. The P/E ratio is 39.4, which is above the sector median (25.0). Market capitalization is 10.59 billion USD, rank 24 among 372 stocks of the same industry with a known capitalization.
Closing prices for 09 October 2026
Next earnings report: 26 October 2026 · Earnings calendar
BioMarin Pharmaceutical Inc. trades on Nasdaq under the ticker BMRN. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks BMRN has traded between 49.26 $ and 70.98 $. As of 09 October 2026 the price stood 25.51 % of the way from the 52-week low to the high.
Over one year BMRN shares rose 0.20 %; over six months they rose 0.50 %. Volatility over 90 days is 28.74 %. Dividends are not included: this is price change only, as of 09 October 2026.
BMRN trades at a price-to-earnings ratio of 39.4, above the sector median of 25.0. Price to sales is 3.3, below the sector median of 4.0. Price to book is 1.7, below the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 54.80 | 55.98 | 54.48 | 54.80 | 2M |
| 08 October 2026 | 54.95 | 54.97 | 53.90 | 54.89 | 3M |
| 07 October 2026 | 56.05 | 56.60 | 54.76 | 55.20 | 2M |
| 06 October 2026 | 57.54 | 57.88 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
BioMarin treats rare inherited diseases — where patients are few and no treatment existed at all.
The rare disease market works unlike the ordinary one: patients number in thousands rather than millions, but there are no competitors and a course costs hundreds of thousands. Diagnosis is genetic, so a patient can be found directly and no large sales force is needed.
The main product of recent years is a drug for achondroplasia, a bone growth disorder in children: it lets a child grow closer to normal, and treatment lasts years. The rest of the portfolio is enzyme replacement therapy for other rare syndromes. Risks: insurer decisions on covering expensive treatment, competition and trial outcomes. The company pays no dividend.
Address:105 DIGITAL DRIVE, NOVATO, CA, 94949, US
BioMarin Pharmaceutical Inc. reported revenue of 3.2B $ and net income of 269M $ over the last four quarters. Net margin is 8.29 %. Revenue changed by +9.90 % year over year. Earnings per share are 1.39 $. Market capitalisation is 10.6B $.
BMRN has a return on equity of 4.33 %, above the sector median of −41.68 %. Return on assets is 3.13 %, above the sector median of −32.11 %. Operating margin is 9.72 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 55.76 |
| 56.22 |
| 4M |
| 05 October 2026 | 57.11 | 58.11 | 56.82 | 57.54 | 2M |
| 02 October 2026 | 58.52 | 58.73 | 57.15 | 57.18 | 2M |
| 01 October 2026 | 59.81 | 60.16 | 58.39 | 58.44 | 2M |
| 30 September 2026 | 59.90 | 60.71 | 59.37 | 60.00 | 2M |
| 29 September 2026 | 59.24 | 60.09 | 58.96 | 59.87 | 2M |
| 28 September 2026 | 59.87 | 60.07 | 58.74 | 59.46 | 2M |
| 25 September 2026 | 61.50 | 61.50 | 60.17 | 60.26 | 2M |
| 24 September 2026 | 62.21 | 62.33 | 61.13 | 61.35 | 2M |
| 23 September 2026 | 63.68 | 64.00 | 61.58 | 62.21 | 2M |
| 22 September 2026 | 64.34 | 64.79 | 63.35 | 63.37 | 2M |
| 21 September 2026 | 64.35 | 64.96 | 63.58 | 64.06 | 2M |
| 18 September 2026 | 65.25 | 65.29 | 63.84 | 63.94 | 4M |
| 17 September 2026 | 65.34 | 66.21 | 64.97 | 65.08 | 1M |
| 16 September 2026 | 64.48 | 65.67 | 64.34 | 64.73 | 2M |
| 15 September 2026 | 65.78 | 65.78 | 63.85 | 64.45 | 2M |
| 14 September 2026 | 66.27 | 66.88 | 65.72 | 66.41 | 1M |